Company Profile

1. Corporate Factsheet May 2011 • Company Snapshot • Symbol: NVIV.ob 52-Wk Range: $0.60 - $4.00 Fully Diluted Shares Outstanding: 65.2mm • Exchange: OTC.BB Recent Close: $0.89 Market Cap: $55mm FY End: December 31 • Company Profile • InVivo Therapeutics Holdings Corp. (OTCBB: NVIV) is a Cambridge, MA medical device company focused on utilizing polymers as a platform technology to develop and commercialize groundbreaking treatments for spinal cord injuries (SCI). The company was founded in 2005 on the basis of proprietary technology co-invented by Robert Langer, Sc.D., Professor at Massachusetts Institute of Technology, and Joseph P. Vacanti, M.D., who is affiliated with Massachusetts General Hospital in Boston. • The financial impact of SCI, as reported by the National Spinal Cord Injury Statistics Center, is staggering. First year, “cost of care” ranges from $244,562 to $829,843, depending on severity of injury. However, only a very small percentage of patients ever regain full function as current medical interventions address only the symptoms of SCI rather than the underlying neurological pathology. Currently, there are no successful treatment options for spinal cord injuries. • InVivo’s takes a novel approach to SCI. Instead of focusing exclusively on regeneration, InVivo concentrates on neuroprotection: protecting the spinal cord by mitigating the bleeding, inflammation, and further cell death that result from the body’s immune response to SCI. By minimizing these secondary injury processes, and by supporting subsequent repair and recovery, the body can locally reorganize toward functional recovery through the spared healthy tissue. This process, known as neuroplasticity, may result in partial functional recovery. • Technology Platform Highlights: A New Paradigm for SCI Treatment • InVivo’s technologies encompass multiple strategies involving biomaterials, U.S. Food & Drug Administration (FDA) • approved drugs, growth factors, and human neural stem cells (hNSCs). The company is developing three products: • Market Opportunity and Lucrative Grown Potential • In the United States it is estimated that there are 12,000 new cases of spinal cord injury each year, and approximately 1,275,000 people are currently living with paralysis due to SCI. InVivo’s first biopolymer device for acute SCI is scheduled to commence human clinical trials by the end of 2011and the company estimates a total addressable market for acute SCI for its first product of approximately $10 billion. • InVivo’s products offer explosive growth potential with significant reward, while risk is mitigated due to a shorter regulatory approval process for medical devices. Biopolymer Scaffold to Treat SCI: A novel surgical device designed for implantation into an acute SCI lesion. The scaffold is developed from a biodegradable and biocompatible polymer approved by the FDA for surgical sutures. The device degrades naturally inside the body over a desired time period to maximize efficacy without requiring subsequent removal. Injectable Hydrogel for Local Drug Delivery: An injectable hydrogel designed for local controlled release of drugs to counteract the inflammatory environment that results during secondary injury after closed-wound SCI. Biopolymer Scaffold Seeded with Autologous Human Neural Stem Cells: Extends the biopolymer platform technology to treat both acute and chronic SCI by seeding the patient’s own stem cells into the scaffold, which acts as a synthetic extracellular matrix. Sources: Christopher & Dana Reeve Foundation, and National Spinal Cord Injury Statistical Center. “One Degree of Separation: Paralysis and Spinal Cord Injury in the United States” 2010. www.invivotherapeutics.com

2. Management Team, Directors & Advisors Frank Reynolds Chairman of the Board Chief Executive Officer Chief Financial Officer Christopher Pritchard, PhD Chief Science Officer Eric J. Woodard, MD Chief Medical Officer George Nolen Lead Director Richard J. Roberts, PhD Director Christi M. Pedra Director Adam K. Stern Director Robert S. Langer, ScD Scientific Advisory Board Reggie Edgerton, PhD Scientific Advisory Board Jonathan Slotkin, MD Scientific Advisory Board Todd J. Albert, MD Scientific Advisory Board Paul Mraz Business Advisory Board David W. Feigal Jr., MD Business Advisory Board Investor Contact: One Broadway, 14th FloorCambridge, MA 02142617-475-1520 IR@invivotherapeutics.com Groundbreaking Results Demonstrate Proof of Concept InVivo has demonstrated the proof of concept for its SCI therapy in primate and rodent animal models. The company is the first in history to successfully demonstrate functional improvement in a paralyzed non-human primate and believes this model is the best surrogate for how the products will work in humans. Research from this landmark study(Journal of Neuroscience Methods, 188 (2010) 258-269) received the 2011 Apple Award recognizing excellence in SCI research from the American Spinal Injury Association (ASIA). Seminal Rodent Study – 2002 Results from the scaffold configured to treat SCI showed functional locomotive improvement as early as two weeks post-injury. Subjects demonstrated sustainable functional recovery and no adverse pathological reactions to the product. Non-Human Primate Studies – 2008 through 2010 Behavioral scoring was performed along with collection of EMG and kinematic data. On average, all treated animals demonstrated an improved level of functional recovery compared to the control animals. Safe Harbor Statement This factsheet contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential or financial performance. No forward- looking statement can be guaranteed and actual results may differ materially from those projected. InVivo Therapeutics undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Forward-looking statements in this presentation should be evaluated together with the many uncertainties that affect InVivo's business, particularly those mentioned in the risk factors and cautionary statements in the Company’s filings with the Securities and Exchange Commission. Forward-looking statements represent management's current expectations and are inherently uncertain. We do not undertake any obligation to update forward-looking statements made by us. FIGURE6.LEFT HIND LIMB NEUROMOTOR PERFORMANCE FROM ST.KITTS PRIMATE GREEN PILOT STUDY (2008) (Scaffold +hNSC: n=2 expect for Day 1 & Day 44, where n=1; Scaffold alone: n=1, No Treatment:n=1) • FIGURE 5. IPSILATERAL-LESIONED SIDE BBB OPEN FIELD WALKING SCORE FROM RODENT STUDY (Teng, Lavik, et al. 2002) Strong IP Protection and Robust Timeline InVivo plans to begin a pilot clinical study to evaluate the scaffold-only device in 10 acute SCI patients by the end of 2011, followed by a larger pivotal human study. If approved for commercialization, InVivo’s products will represent an entirely new therapeutic class protected by 10 issued US patents and 3 pending US patents as well as 67 international patents and 34 international patents pending stemming form over a decade of research. The patents cover the use of any biomaterials to treat SCI alone or in combination with any drugs or cells. January 2006 – June 2008 June 2011 – December 2012 Complete Preclinical Studies Human Clinical Trials Complete Non-Human Primate Efficacy Studies Submit to FDA for Approval April 2008 – August 2010 December 2012